Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | ATIC | P31939 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.61 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6622354 | 0.83 | MAPT (0.68) | HSD17B10HPGDCYP2C9THRBTSHR | |
| SCHEMBL9618861 | 0.82 | HSD17B10 (0.74) | HSD17B10HPGDCYP2C9THRBTSHR | |
| SCHEMBL5539615 | 0.82 | HSD17B10 (0.88) | HSD17B10HPGDCYP2C9THRBTSHR | |
| SCHEMBL317180 | 0.80 | THRB (1.00) | HSD17B10HPGDCYP2C9THRBTSHR | |
| SCHEMBL485382 | 0.79 | KMT2A (0.50) | HSD17B10HPGDCYP2C9THRBTSHR | |
| SCHEMBL2790522 | 0.79 | HSD17B10 (0.54) | HSD17B10HPGDCYP2C9THRBTSHR | |
| SCHEMBL2790156 | 0.78 | HSD17B10 (0.57) | HSD17B10HPGDCYP2C9THRBTSHR | |
| SCHEMBL2786889 | 0.78 | HSD17B10 (0.57) | HSD17B10HPGDCYP2C9THRBTSHR | |
| SCHEMBL12818517 | 0.77 | HSD17B10 (0.67) | HSD17B10HPGDCYP2C9THRBTSHR | |
| SCHEMBL22213017 | 0.77 | HSD17B10 (0.67) | HSD17B10HPGDCYP2C9THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| WO-2008000409-A1 | NEW CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000409-A1 | NEW CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| CN-101094830-A | Fused bicyclic carboxamide derivatives for use as CXCR2 inhibitors in the treatment of inflammation | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-12-26 | — | — | CN | disclosed |
| EP-1836158-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676834-A1 | Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation | Sanofi-Aventis Deutschland GmbH (DE) | 2006-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | HSD17B10 2585/4885HPGD 565/4885CYP2C9 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.